Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosmidomycin + piperaquine combination therapy - Jomaa Pharma/Medicines for Malaria venture

Next Previous
Search
Drug Profile

Fosmidomycin + piperaquine combination therapy - Jomaa Pharma/Medicines for Malaria venture

Alternative Names: Piperaquine + fosmidomycin combination therapy - Jomaa Pharma/Medicines for Malaria Venture

Latest Information Update: 03 Mar 2017

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jomaa Pharma; Justus Liebig University
  • Developer Jomaa Pharma
  • Class Organophosphorus compounds; Phosphonic acids; Quinolones; Small molecules
  • Mechanism of Action Oxidoreductase inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Malaria

Most Recent Events

  • 03 Mar 2017 Fosmidomycin + piperaquine combination therapy is still at phase II development stage for Malaria in Gabon (PO)
  • 03 Mar 2017 Fosmidomycin + piperaquine combination therapy - Jomaa Pharma/Medicines for Malaria venture is available for licensing as of 03 Mar 2017. www.jomaa-pharma.com
  • 14 Nov 2016 Jomaa Pharma completes a phase IIa trial in Malaria (In children, In adults) in Gabon

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top